EX-99.1 2 y65676exv99w1.htm EX-99.1: FREQUENTLY ASKED QUESTIONS AND ANSWERS EX-99.1
Exhibit 99.1
August 18, 2008 — Frequently Asked Questions and Answers – (FAQs)
From time to time, Investor Relations will provide FAQs on various topics of interest. The following is a recent FAQ.
     
Q
  What are the IMS prescription volumes for VYTORIN and ZETIA?
 
    
A
  U.S. Total Prescription Volume (000’s)
                                                         
    January   February   March   April   May   June   July
    2008   2008   2008   2008   2008   2008   2008
 
Cholesterol Management Market
     20,402       18,941       19,687       19,543       19,804       19,398       20,294  
Total Merck/Schering-Plough Franchise
     3,205       2,773       2,803       2,492       2,463       2,352       2,378  
VYTORIN
     1,839       1,597       1,610       1,420       1,404       1,330       1,339  
ZETIA
     1,366       1,176       1,193       1,072       1,060       1,022       1,039  
Source: IMS’ National Prescription Audit Plus (NPA+) as of August 13, 2008, which includes routine refinements by IMS to previously published data.
DISCLOSURE NOTICE: The information in the frequently asked questions included in this FAQ, and in other written and oral statements about Schering-Plough and its business made by Schering-Plough or its officers from time to time, includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to prescription trends for VYTORIN and ZETIA.
Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough’s forward-looking statements, including market forces (such as customer buying patterns); economic factors; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the timing and outcomes of the regulatory process; and prescriber, patient and media reaction to data obtained from post-marketing clinical trials, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part II, Item 1A. “Risk Factors” in Schering-Plough’s 10-Q for the quarterly period ended June 30, 2008, filed August 1, 2008.

Page 6